The V86M mutation in HIV-1 capsid confers resistance to TRIM5α by abrogation of cyclophilin a-dependent restriction and enhancement of viral nuclear import

Retrovirology

Volumn 10, Issue 1, 2013, Pages

  Veillette, Maxime ^a   Bichel, Katsiaryna ^b   Pawlica, Paulina ^a   Freund, Stefan M V ^b   Plourde, Mélodie B ^a   Pham, Quang Toan ^a   Reyes Moreno, Carlos ^a   James, Leo C ^b   Berthoux, Lionel ^a  

^a UNIVERSITÉ DU QUÉBEC À TROIS RIVIÈRES   (Canada)

^b MRC LABORATORY OF MOLECULAR BIOLOGY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHILIN A; TRIPARTITE MOTIF PROTEIN 5; VIRUS DNA; VIRUS NUCLEOPROTEIN;

ANIMAL CELL; ARTICLE; CAT; CONTROLLED STUDY; EMBRYO; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MOLECULAR PATHOLOGY; NONHUMAN; NUCLEAR IMPORT; NUCLEAR MAGNETIC RESONANCE; POLYMERASE CHAIN REACTION; PROTEIN CONFORMATION; PROTEIN DNA BINDING; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN PROTEIN INTERACTION; VIRUS CAPSID; VIRUS CELL INTERACTION; VIRUS REPLICATION; VIRUS RESISTANCE;

ACTIVE TRANSPORT, CELL NUCLEUS; CARRIER PROTEINS; CELL LINE; CYCLOPHILIN A; HIV CORE PROTEIN P24; HIV-1; HUMANS; MUTANT PROTEINS; MUTATION, MISSENSE;

HUMAN IMMUNODEFICIENCY VIRUS 1; MACACA MULATTA; MIRIDAE; SIMIAE;

EID: 84874370905     PISSN: None     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/1742-4690-10-25     Document Type: Article

References (69)

1. Stremlau M, Owens CM, Perron MJ, Kiessling M, Autissier P, Sodroski J. The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old world monkeys. Nature 2004, 427:848-853. 10.1038/nature02343, 14985764.
2. Owens CM, Yang PC, Gottlinger H, Sodroski J. Human and simian immunodeficiency virus capsid proteins are major viral determinants of early, postentry replication blocks in simian cells. J Virol 2003, 77:726-731. 10.1128/JVI.77.1.726-731.2003, 140632, 12477877.
3. Perez-Caballero D, Hatziioannou T, Zhang F, Cowan S, Bieniasz PD. Restriction of human immunodeficiency virus type 1 by TRIM-CypA occurs with rapid kinetics and independently of cytoplasmic bodies, ubiquitin, and proteasome activity. J Virol 2005, 79:15567-15572. 10.1128/JVI.79.24.15567-15572.2005, 1316013, 16306627.
4. Cowan S, Hatziioannou T, Cunningham T, Muesing MA, Gottlinger HG, Bieniasz PD. Cellular inhibitors with Fv1-like activity restrict human and simian immunodeficiency virus tropism. Proc Natl Acad Sci USA 2002, 99:11914-11919. 10.1073/pnas.162299499, 129368, 12154227.
5. Forshey BM, Shi J, Aiken C. Structural requirements for recognition of the human immunodeficiency virus type 1 core during host restriction in owl monkey cells. J Virol 2005, 79:869-875. 10.1128/JVI.79.2.869-875.2005, 538572, 15613315.
6. Ikeda Y, Ylinen LM, Kahar-Bador M, Towers GJ. Influence of gag on human immunodeficiency virus type 1 species-specific tropism. J Virol 2004, 78:11816-11822. 10.1128/JVI.78.21.11816-11822.2004, 523279, 15479823.
7. Shi J, Aiken C. Saturation of TRIM5 alpha-mediated restriction of HIV-1 infection depends on the stability of the incoming viral capsid. Virology 2006, 350:493-500. 10.1016/j.virol.2006.03.013, 16624363.
8. Stremlau M, Perron M, Lee M, Li Y, Song B, Javanbakht H, Diaz-Griffero F, Anderson DJ, Sundquist WI, Sodroski J. Specific recognition and accelerated uncoating of retroviral capsids by the TRIM5alpha restriction factor. Proc Natl Acad Sci USA 2006, 103:5514-5519. 10.1073/pnas.0509996103, 1459386, 16540544.
9. Langelier CR, Sandrin V, Eckert DM, Christensen DE, Chandrasekaran V, Alam SL, Aiken C, Olsen JC, Kar AK, Sodroski JG, Sundquist WI. Biochemical characterization of a recombinant TRIM5alpha protein that restricts human immunodeficiency virus type 1 replication. J Virol 2008, 82:11682-11694. 10.1128/JVI.01562-08, 2583683, 18799573.
10. Sebastian S, Luban J. TRIM5alpha selectively binds a restriction-sensitive retroviral capsid. Retrovirology 2005, 2:40. 10.1186/1742-4690-2-40, 1166576, 15967037.
11. Perez-Caballero D, Hatziioannou T, Yang A, Cowan S, Bieniasz PD. Human tripartite motif 5alpha domains responsible for retrovirus restriction activity and specificity. J Virol 2005, 79:8969-8978. 10.1128/JVI.79.14.8969-8978.2005, 1168745, 15994791.
12. Kar AK, Diaz-Griffero F, Li Y, Li X, Sodroski J. Biochemical and biophysical characterization of a chimeric TRIM21-TRIM5alpha protein. J Virol 2008, 82:11669-11681. 10.1128/JVI.01559-08, 2583655, 18799572.
13. Campbell EM, Perez O, Anderson JL, Hope TJ. Visualization of a proteasome-independent intermediate during restriction of HIV-1 by rhesus TRIM5alpha. J Cell Biol 2008, 180:549-561. 10.1083/jcb.200706154, 2234241, 18250195.
14. Black LR, Aiken C. TRIM5alpha disrupts the structure of assembled HIV-1 capsid complexes in vitro. J Virol 2010, 84:6564-6569. 10.1128/JVI.00210-10, 2903270, 20410272.
15. Perron MJ, Stremlau M, Lee M, Javanbakht H, Song B, Sodroski J. The human TRIM5alpha restriction factor mediates accelerated uncoating of the N-tropic murine leukemia virus capsid. J Virol 2007, 81:2138-2148. 10.1128/JVI.02318-06, 1865943, 17135314.
16. Zhao G, Ke D, Vu T, Ahn J, Shah VB, Yang R, Aiken C, Charlton LM, Gronenborn AM, Zhang P. Rhesus TRIM5alpha disrupts the HIV-1 capsid at the inter-hexamer interfaces. PLoS Pathog 2011, 7:e1002009. 10.1371/journal.ppat.1002009, 3063768, 21455494.
17. Anderson JL, Campbell EM, Wu X, Vandegraaff N, Engelman A, Hope TJ. Proteasome inhibition reveals that a functional preintegration complex intermediate can be generated during restriction by diverse TRIM5 proteins. J Virol 2006, 80:9754-9760. 10.1128/JVI.01052-06, 1617233, 16973579.
18. Diaz-Griffero F, Li X, Javanbakht H, Song B, Welikala S, Stremlau M, Sodroski J. Rapid turnover and polyubiquitylation of the retroviral restriction factor TRIM5. Virology 2006, 349:300-315. 10.1016/j.virol.2005.12.040, 16472833.
19. Rold CJ, Aiken C. Proteasomal degradation of TRIM5alpha during retrovirus restriction. PLoS Pathog 2008, 4:e1000074. 10.1371/journal.ppat.1000074, 2374908, 18497858.
20. Lienlaf M, Hayashi F, Di Nunzio F, Tochio N, Kigawa T, Yokoyama S, Diaz-Griffero F. Contribution of E3-ubiquitin ligase activity to HIV-1 restriction by TRIM5alpha(rh): structure of the RING domain of TRIM5alpha. J Virol 2011, 85:8725-8737. 10.1128/JVI.00497-11, 3165826, 21734049.
21. Berthoux L, Sebastian S, Sokolskaja E, Luban J. Lv1 inhibition of human immunodeficiency virus type 1 is counteracted by factors that stimulate synthesis or nuclear translocation of viral cDNA. J Virol 2004, 78:11739-11750. 10.1128/JVI.78.21.11739-11750.2004, 523245, 15479815.
22. Wu X, Anderson JL, Campbell EM, Joseph AM, Hope TJ. Proteasome inhibitors uncouple rhesus TRIM5alpha restriction of HIV-1 reverse transcription and infection. Proc Natl Acad Sci USA 2006, 103:7465-7470. 10.1073/pnas.0510483103, 1464362, 16648264.
23. Hatziioannou T, Perez-Caballero D, Cowan S, Bieniasz PD. Cyclophilin interactions with incoming human immunodeficiency virus type 1 capsids with opposing effects on infectivity in human cells. J Virol 2005, 79:176-183. 10.1128/JVI.79.1.176-183.2005, 538701, 15596813.
24. Li Y, Kar AK, Sodroski J. Target cell type-dependent modulation of human immunodeficiency virus (HIV-1) capsid disassembly by cyclophilin a. J Virol 2009, 83:10951-10962. 10.1128/JVI.00682-09, 2772774, 19656870.
25. Sokolskaja E, Sayah DM, Luban J. Target cell cyclophilin A modulates human immunodeficiency virus type 1 infectivity. J Virol 2004, 78:12800-12808. 10.1128/JVI.78.23.12800-12808.2004, 524981, 15542632.
26. Keckesova Z, Ylinen LM, Towers GJ. Cyclophilin A renders human immunodeficiency virus type 1 sensitive to Old World monkey but not human TRIM5 alpha antiviral activity. J Virol 2006, 80:4683-4690. 10.1128/JVI.80.10.4683-4690.2006, 1472055, 16641261.
27. Sokolskaja E, Berthoux L, Luban J. Cyclophilin A and TRIM5alpha independently regulate human immunodeficiency virus type 1 infectivity in human cells. J Virol 2006, 80:2855-2862. 10.1128/JVI.80.6.2855-2862.2006, 1395419, 16501094.
28. Berthoux L, Sebastian S, Sokolskaja E, Luban J. Cyclophilin A is required for TRIM5{alpha}-mediated resistance to HIV-1 in Old World monkey cells. Proc Natl Acad Sci USA 2005, 102:14849-14853. 10.1073/pnas.0505659102, 1239943, 16203999.
29. Stremlau M, Song B, Javanbakht H, Perron M, Sodroski J. Cyclophilin A: an auxiliary but not necessary cofactor for TRIM5alpha restriction of HIV-1. Virology 2006, 351:112-120. 10.1016/j.virol.2006.03.015, 16643975.
30. Kootstra NA, Munk C, Tonnu N, Landau NR, Verma IM. Abrogation of postentry restriction of HIV-1-based lentiviral vector transduction in simian cells. Proc Natl Acad Sci USA 2003, 100:1298-1303. 10.1073/pnas.0337541100, 298767, 12547912.
31. Franke EK, Yuan HE, Luban J. Specific incorporation of cyclophilin A into HIV-1 virions. Nature 1994, 372:359-362. 10.1038/372359a0, 7969494.
32. Luban J, Bossolt KL, Franke EK, Kalpana GV, Goff SP. Human immunodeficiency virus type 1 Gag protein binds to cyclophilins A and B. Cell 1993, 73:1067-1078. 10.1016/0092-8674(93)90637-6, 8513493.
33. Bosco DA, Eisenmesser EZ, Pochapsky S, Sundquist WI, Kern D. Catalysis of cis/trans isomerization in native HIV-1 capsid by human cyclophilin A. Proc Natl Acad Sci USA 2002, 99:5247-5252. 10.1073/pnas.082100499, 122755, 11929983.
34. Gamble TR, Vajdos FF, Yoo S, Worthylake DK, Houseweart M, Sundquist WI, Hill CP. Crystal structure of human cyclophilin a bound to the amino-terminal domain of HIV-1 capsid. Cell 1996, 87:1285-1294. 10.1016/S0092-8674(00)81823-1, 8980234.
35. Pacheco B, Finzi A, Stremlau M, Sodroski J. Adaptation of HIV-1 to cells expressing rhesus monkey TRIM5alpha. Virology 2010, 408:204-212. 10.1016/j.virol.2010.09.019, 2975777, 20956011.
36. Li Y, Li X, Stremlau M, Lee M, Sodroski J. Removal of arginine 332 allows human TRIM5alpha to bind human immunodeficiency virus capsids and to restrict infection. J Virol 2006, 80:6738-6744. 10.1128/JVI.00270-06, 1489046, 16809279.
37. Maillard PV, Reynard S, Serhan F, Turelli P, Trono D. Interfering residues narrow the spectrum of MLV restriction by human TRIM5alpha. PLoS Pathog 2007, 3:e200. 10.1371/journal.ppat.0030200, 2156100, 18166079.
38. Pham QT, Bouchard A, Grutter MG, Berthoux L. Generation of human TRIM5alpha mutants with high HIV-1 restriction activity. Gene Ther 2010, 17:859-871. 10.1038/gt.2010.40, 20357830.
39. Stremlau M, Perron M, Welikala S, Sodroski J. Species-specific variation in the B30.2(SPRY) domain of TRIM5alpha determines the potency of human immunodeficiency virus restriction. J Virol 2005, 79:3139-3145. 10.1128/JVI.79.5.3139-3145.2005, 548447, 15709033.
40. Yap MW, Nisole S, Stoye JP. A single amino acid change in the SPRY domain of human Trim5alpha leads to HIV-1 restriction. Curr Biol 2005, 15:73-78. 10.1016/j.cub.2004.12.042, 15649369.
41. Anderson JS, Javien J, Nolta JA, Bauer G. Preintegration HIV-1 inhibition by a combination lentiviral vector containing a chimeric TRIM5 alpha protein, a CCR5 shRNA, and a TAR decoy. Mol Ther 2009, 17:2103-2114. 10.1038/mt.2009.187, 2814390, 19690520.
42. Pham QT, Veillette M, Brandariz-Nunez A, Pawlica P, Thibert-Lefebvre C, Chandonnet N, Diaz-Griffero F, Berthoux L. A novel aminoacid determinant of HIV-1 restriction in the TRIM5alpha variable 1 region isolated in a random mutagenic screen. Virus Res 2013, Epub ahead of print.
43. Towers GJ, Hatziioannou T, Cowan S, Goff SP, Luban J, Bieniasz PD. Cyclophilin A modulates the sensitivity of HIV-1 to host restriction factors. Nat Med 2003, 9:1138-1143. 10.1038/nm910, 12897779.
44. Bérubé J, Bouchard A, Berthoux L. Both TRIM5alpha and TRIMCyp have only weak antiviral activity in canine D17 cells. Retrovirology 2007, 4:68. 10.1186/1742-4690-4-68, 2064933, 17892575.
45. Bosco DA, Eisenmesser EZ, Clarkson MW, Wolf-Watz M, Labeikovsky W, Millet O, Kern D. Dissecting the microscopic steps of the cyclophilin A enzymatic cycle on the biological HIV-1 capsid substrate by NMR. J Mol Biol 2010, 403:723-738. 10.1016/j.jmb.2010.08.001, 20708627.
46. Sakuma R, Noser JA, Ohmine S, Ikeda Y. Rhesus monkey TRIM5alpha restricts HIV-1 production through rapid degradation of viral Gag polyproteins. Nat Med 2007, 13:631-635. 10.1038/nm1562, 17435772.
47. Zhang F, Perez-Caballero D, Hatziioannou T, Bieniasz PD. No effect of endogenous TRIM5alpha on HIV-1 production. Nat Med 2008, 14:235-236. author reply 236-238, 10.1038/nm0308-235, 18323834.
48. Groot F, Welsch S, Sattentau QJ. Efficient HIV-1 transmission from macrophages to T cells across transient virological synapses. Blood 2008, 111:4660-4663. 10.1182/blood-2007-12-130070, 18296630.
49. Haller C, Fackler OT. HIV-1 at the immunological and T-lymphocytic virological synapse. Biol Chem 2008, 389:1253-1260.
50. Rudnicka D, Feldmann J, Porrot F, Wietgrefe S, Guadagnini S, Prevost MC, Estaquier J, Haase AT, Sol-Foulon N, Schwartz O. Simultaneous cell-to-cell transmission of human immunodeficiency virus to multiple targets through polysynapses. J Virol 2009, 83:6234-6246. 10.1128/JVI.00282-09, 2687379, 19369333.
51. Richardson MW, Carroll RG, Stremlau M, Korokhov N, Humeau LM, Silvestri G, Sodroski J, Riley JL. Mode of transmission affects the sensitivity of human immunodeficiency virus type 1 to restriction by rhesus TRIM5alpha. J Virol 2008, 82:11117-11128. 10.1128/JVI.01046-08, 2573261, 18768965.
52. Kuritzkes DR. Drug resistance in HIV-1. Curr Opin Virol 2011, 1:582-589. 10.1016/j.coviro.2011.10.020, 3232467, 22162985.
53. Lee K, Ambrose Z, Martin TD, Oztop I, Mulky A, Julias JG, Vandegraaff N, Baumann JG, Wang R, Yuen W. Flexible use of nuclear import pathways by HIV-1. Cell Host Microbe 2010, 7:221-233. 10.1016/j.chom.2010.02.007, 2841689, 20227665.
54. Price AJ, Fletcher AJ, Schaller T, Elliott T, Lee K, Kewalramani VN, Chin JW, Towers GJ, James LC. CPSF6 Defines a Conserved Capsid Interface that Modulates HIV-1 Replication. PLoS Pathog 2012, 8:e1002896. 10.1371/journal.ppat.1002896, 3431306, 22956906.
55. Lin TY, Emerman M. Determinants of cyclophilin A-dependent TRIM5 alpha restriction against HIV-1. Virology 2008, 379:335-341. 10.1016/j.virol.2008.06.037, 2615586, 18678385.
56. Matreyek KA, Engelman A. The requirement for nucleoporin NUP153 during human immunodeficiency virus type 1 infection is determined by the viral capsid. J Virol 2011, 85:7818-7827. 10.1128/JVI.00325-11, 3147902, 21593146.
57. Schaller T, Ocwieja KE, Rasaiyaah J, Price AJ, Brady TL, Roth SL, Hue S, Fletcher AJ, Lee K, KewalRamani VN. HIV-1 capsid-cyclophilin interactions determine nuclear import pathway, integration targeting and replication efficiency. PLoS Pathog 2011, 7:e1002439. 10.1371/journal.ppat.1002439, 3234246, 22174692.
58. Berthoux L, Sebastian S, Sayah DM, Luban J. Disruption of human TRIM5alpha antiviral activity by nonhuman primate orthologues. J Virol 2005, 79:7883-7888. 10.1128/JVI.79.12.7883-7888.2005, 1143641, 15919943.
59. Sebastian S, Sokolskaja E, Luban J. Arsenic counteracts human immunodeficiency virus type 1 restriction by various TRIM5 orthologues in a cell type-dependent manner. J Virol 2006, 80:2051-2054. 10.1128/JVI.80.4.2051-2054.2006, 1367146, 16439561.
60. Sayah DM, Sokolskaja E, Berthoux L, Luban J. Cyclophilin A retrotransposition into TRIM5 explains owl monkey resistance to HIV-1. Nature 2004, 430:569-573. 10.1038/nature02777, 15243629.
61. Berthoux L, Towers GJ, Gurer C, Salomoni P, Pandolfi PP, Luban J. As(2)O(3) enhances retroviral reverse transcription and counteracts Ref1 antiviral activity. J Virol 2003, 77:3167-3180. 10.1128/JVI.77.5.3167-3180.2003, 149754, 12584341.
62. Naviaux RK, Costanzi E, Haas M, Verma IM. The pCL vector system: rapid production of helper-free, high-titer, recombinant retroviruses. J Virol 1996, 70:5701-5705. 190538, 8764092.
63. Zufferey R, Nagy D, Mandel RJ, Naldini L, Trono D. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol 1997, 15:871-875. 10.1038/nbt0997-871, 9306402.
64. Adachi A, Gendelman HE, Koenig S, Folks T, Willey R, Rabson A, Martin MA. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol 1986, 59:284-291. 253077, 3016298.
65. Dufresne M, Dumas G, Asselin E, Carrier C, Pouliot M, Reyes-Moreno C. Pro-inflammatory type-1 and anti-inflammatory type-2 macrophages differentially modulate cell survival and invasion of human bladder carcinoma T24 cells. Mol Immunol 2011, 48:1556-1567. 10.1016/j.molimm.2011.04.022, 21601924.
66. Butler SL, Hansen MS, Bushman FD. A quantitative assay for HIV DNA integration in vivo. Nat Med 2001, 7:631-634. 10.1038/87979, 11329067.
67. Price AJ, Marzetta F, Lammers M, Ylinen LM, Schaller T, Wilson SJ, Towers GJ, James LC. Active site remodeling switches HIV specificity of antiretroviral TRIMCyp. Nat Struct Mol Biol 2009, 16:1036-1042. 10.1038/nsmb.1667, 3556581, 19767750.
68. Bosco DA, Kern D. Catalysis and binding of cyclophilin A with different HIV-1 capsid constructs. Biochemistry 2004, 43:6110-6119. 10.1021/bi049841z, 15147195.
69. Farrow NA, Zhang O, Forman-Kay JD, Kay LE. A heteronuclear correlation experiment for simultaneous determination of 15 N longitudinal decay and chemical exchange rates of systems in slow equilibrium. J Biomol NMR 1994, 4:727-734. 10.1007/BF00404280, 7919956.